Answers are grounded in this paper and cite their sources.
The BCL-2/BCL-XL inhibitor navitoclax has shown promise for the treatment of cancer but on-target toxicities have limited its utility. Recently, the generation of selective BCL-2 family inhibitors has enabled a careful dissection of BCL-2 biology, and early work indicates that these molecules have improved therapeutic profiles for the treatment of cancer.
No takes yet. Share an insight, caveat, or question.
Joel D. Leverson (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: